ChemicalBook > CAS DataBase List > Magrolimab

Magrolimab

Product Name
Magrolimab
CAS No.
2169232-81-7
Chemical Name
Magrolimab
Synonyms
Magrolimab;Magrolimab (anti-CD47);Research Grade Magrolimab;Hu5F9-G4|||Magrolimab (anti-CD47);Research Grade Magrolimab(DHG17601)
CBNumber
CB78081141
Formula Weight
0
MOL File
Mol file
More
Less

Magrolimab Property

form 
Liquid
color 
Colorless to light yellow
More
Less

Hazard and Precautionary Statements (GHS)

More
Less

Magrolimab Chemical Properties,Usage,Production

Uses

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 antibody. Magrolimab can block the "don't eat me" signal of CD47, thereby promoting macrophage mediated phagocytosis. Magrolimab has antitumor activity in malignant bone tumors and breast cancer[1][2][3].

in vivo

Magrolimab (12-100 μg; once daily; 10 days; i.p.) exhibits anti-tumor activity in mice with Ewing's sarcoma[1]. Magrolimab (250 μg; once every two days; 7 weeks; i.p.) combined with trastuzumab (HY-P9907) can eliminate HER2 positive breast cancer cells in breast cancer mice and overcome the tolerance of trastuzumab[2].

Animal Model:Humanized and non-humanized ES xenograft NSG-SGM3 mice[1].
Dosage:12-100 μg
Administration:Intraperitoneal injection (i.p.); once daily; 10 days
Result:Inhibited tumor growth and lung metastasis, and prolonged animal survival time.
Animal Model:4-8 weeks old NSG female breast cancer mouse model[2].
Dosage:250 μg
Administration:Intraperitoneal injection (i.p.); once every two days; 7 weeks (implanted GFP/luciferase BT474 cells into the left mammary fat pad of female mice)
Result:Restricted the Growth of HER2 ADCC-Tolerant Tumors.

References

[1] Luo W, et al. A humanized orthotopic mouse model for preclinical evaluation of immunotherapy in Ewing sarcoma. Front Immunol. 2023 Oct 6;14:1277987. DOI:10.3389/fimmu.2023.1277987
[2] Upton R, et al. Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance. Proc Natl Acad Sci U S A. 2021 Jul 20;118(29):e2026849118. DOI:10.1073/pnas.2026849118
[3] Liu Y, et al. PARP inhibition synergizes with CD47 blockade to promote phagocytosis by tumor-associated macrophages in homologous recombination-proficient tumors. Life Sci. 2023 Aug 1;326:121790. DOI:10.1016/j.lfs.2023.121790

Magrolimab Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Magrolimab Suppliers

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Fax
QQ:3008007432
Email
3008007409@qq.com
Country
China
ProdList
71826
Advantage
60
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Fax
QQ:2853530913
Email
2853530910@QQ.com
Country
China
ProdList
8000
Advantage
62
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Country
China
ProdList
1566
Advantage
58
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Fax
QQ:422450190
Email
422450190@qq.com
Country
China
ProdList
10308
Advantage
58
Bide Pharmatech Ltd.
Tel
400-1647117 13681763483
Email
product02@bidepharm.com
Country
China
ProdList
59936
Advantage
58
TargetMol Chemicals Inc.
Tel
4008200310
Email
marketing@tsbiochem.com
Country
China
ProdList
24961
Advantage
58
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
Country
China
ProdList
9868
Advantage
58
Wuhan Jingkangen Biomedical Technology Co., Ltd
Tel
13720134139 086-15871494362 13720134139
Email
orders@jknbiochem.com
Country
China
ProdList
6762
Advantage
58
Shanghai Yifei Biotechnology Co. , Ltd.
Tel
021-65675885 18964387627
Email
customer_service@efebio.com
Country
China
ProdList
11973
Advantage
58
Shanghai Aladdin Biochemical Technology Co.,Ltd.
Tel
400-6206333 13167063860
Email
anhua.mao@aladdin-e.com
Country
China
ProdList
48457
Advantage
58
Shanghai jerryxing Biomedical Technology Co., Ltd
Tel
17721492509; 17721492509
Email
643638326@qq.com
Country
China
ProdList
4970
Advantage
58
Changsha Fuzhen Biotechnology Co.,LTD
Tel
0731-13823398 15111215862
Email
313359644@qq.com
Country
China
ProdList
4161
Advantage
58
Olix (Shanghai) Pharmaceutical Technology Co., Ltd
Tel
17316404525 17316404525
Email
209533805@qq.com
Country
China
ProdList
9766
Advantage
58
Wanxin Biotechnology (Jiaxing) Co., LTD
Tel
0573-83568680 18057391398
Email
3956524501@qq.com
Country
China
ProdList
1442
Advantage
58
Atagenix Laboratories
Tel
027-87008169 17762441161
Email
info@atagenix.com
Country
China
ProdList
10001
Advantage
58
Sangon Biotech (Shanghai) Co.,Ltd.
Tel
400-821-026
Email
Sales@sangon.com
Country
China
ProdList
6710
Advantage
58
AntibodySystem Laboratories SAS
Tel
33175446423
Email
support@antibodysystem.com
Country
China
ProdList
6739
Advantage
58
Biosynth Biological Technology (Suzhou) Co Ltd
Tel
51288865780
Email
sales@biosynth.com
Country
China
ProdList
6051
Advantage
58
Selleck Chemicals
Tel
400-668-6834
Email
info@selleck.cn
Country
China
ProdList
6071
Advantage
58
Cell Sciences
Tel
9785721070
Email
info@cellsciences.com
Country
China
ProdList
6308
Advantage
58
Wuhan Jingkang en Biomedical Technology Co., Ltd
Tel
+8613720134139
Email
orders@jknbiochem.com
Country
China
ProdList
5221
Advantage
58
Guangzhou Xinrong Biotechnology Co., Ltd
Tel
15919646073
Country
CHINA
ProdList
138
Advantage
58
Guangzhou Chuangze Biotechnology Co., Ltd.
Tel
18312220236
Country
CHINA
ProdList
178
Advantage
58
Absin Bioscience Inc.
Tel
--
Fax
--
Email
chenjw@absin.cn
Country
CHINA
ProdList
6208
Advantage
58
Proteintech China
Tel
--
Fax
--
Email
Proteintech-CN@ptglab.com
Country
CHINA
ProdList
6290
Advantage
58

2169232-81-7, MagrolimabRelated Search:


  • Magrolimab
  • Research Grade Magrolimab(DHG17601)
  • Magrolimab (anti-CD47)
  • Hu5F9-G4|||Magrolimab (anti-CD47)
  • Research Grade Magrolimab
  • 2169232-81-7